Nrf2-ARE signals mediated the anti-oxidative action of electroacupuncture in an MPTP mouse model of Parkinson's disease

Free Radical Research

Volumn 49, Issue 11, 2015, Pages 1296-1307

  Lv, E ^a,b   Deng, J ^a   Yu, Y ^a   Wang, Y ^a   Gong, X ^a   Jia, J ^a,c   Wang, X ^a  

^a BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^b WEIFANG MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

anti infl ammation; anti oxidative stress; electroacupuncture; Nrf2 ARE pathway; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALKALINE PHOSPHATASE PLACENTA ISOENZYME; CATALASE; HEME OXYGENASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ELECTROACUPUNCTURE; GENE EXPRESSION; LIPID OXIDATION; MALE; MESENCEPHALON; MICROGLIA; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMMUNOLOGY; METABOLISM; PROCEDURES;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DISEASE MODELS, ANIMAL; ELECTROACUPUNCTURE; MALE; MICE; MICE, INBRED C57BL; NF-E2-RELATED FACTOR 2; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

EID: 84942506441     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2015.1067696     Document Type: Article

References (47)

1. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987;45:19-34.
2. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
3. Dawson TM, Dawson VL. Molecular pathways of neurode-generation in Parkinson's disease. Science 2003;302:819-822.
4. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-795.
5. Wang B, Williamson G. Detection of a nuclear protein which binds specifically to the antioxidant responsive element (ARE) of the human NAD(P)H:quinone oxidoreductase gene. Bio-chim Biophys Acta 1994;1219:645-652.
6. Prestera T, Talalay P, Alam J, Ahn YI, Lee PJ, Choi AM. Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol Med 1995;1:827-837.
7. Favreau LV, Pickett CB. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Identification of regulatory elements controlling basal level expression and inducible expression by planar aromatic compounds and phenolic anti-oxidants. J Biol Chem 1991;266:4556-4561.
8. Mulcahy RT, Gipp JJ. Identification of a putative antioxidant response element in the 5'-flanking region of the human gam-ma-glutamylcysteine synthetase heavy subunit gene. Biochem Biophys Res Commun 1995;209:227-233.
9. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, et al. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 2007;66:75-85.
10. von Otter M, Landgren S, Nilsson S, Celojevic D, Bergstrom P, Hakansson A, et al. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med Genet 2010;11:36.
11. Kaidery NA, Banerjee R, Yang L, Smirnova NA, Hushpulian DM, Liby KT, et al. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal 2013; 18:139-157.
12. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A 2009;106:2933-2938.
13. Kumar H, Koppula S, Kim IS, More SV, Kim BW, Choi DK. Nuclear factor erythroid 2-related factor 2 signaling in Parkinson disease: a promising multi therapeutic target against oxidative stress, neuroinflammation and cell death. CNS Neurol Disord Drug Targets 2012;11:1015-1029.
14. Zhuang X, Wang L. Acupuncture treatment of Parkinson's disease-a report of 29 cases. J Tradit Chin Med 2000; 20: 265-267.
15. Eng ML, Lyons KE, Greene MS, Pahwa R. Open-label trial regarding the use of acupuncture and yin tui na in Parkinson's disease outpatients: a pilot study on efficacy, tolerability, and quality of life. J Altern Complement Med 2006;12:395-399.
16. Shulman LM, Wen X, Weiner WJ, Bateman D, Minagar A, Duncan R, Konefal J. Acupuncture therapy for the symptoms of Parkinson's disease. Mov Disord 2002;17:799-802.
17. Zeng BY, Salvage S, Jenner P. Current development of acupuncture research in Parkinson's disease. Int Rev Neurobiol 2013;111:141-158.
18. Zeng XH, Li QQ, Xu Q, Li F, Liu CZ. Acupuncture mechanism and redox equilibrium. Evid Based Complement Alternat Med 2014;2014:483294.
19. Wattanathorn J, Sutalangka C. Laser Acupuncture at HT7 Acupoint Improves Cognitive Deficit, Neuronal Loss, Oxida-tive Stress, and Functions of Cholinergic and Dopaminergic Systems in Animal Model of Parkinson's Disease. Evid Based Complement Alternat Med 2014;2014:937601.
20. Yu YP, Ju WP, Li ZG, Wang DZ, Wang YC, Xie AM. Acupuncture inhibits oxidative stress and rotational behavior in 6-hydroxydopamine lesioned rat. Brain Res 2010;1336: 58-65.
21. Kim ST, Moon W, Chae Y, Kim YJ, Lee H, Park HJ. The effect of electroaucpuncture for 1-methyl-4-phenyl-1, 2, 3, 6-tetrahy-dropyridine-induced proteomic changes in the mouse striatum. J Physiol Sci 2010;60:27-34.
22. Wang H, Liang X, Wang X, Luo D, Jia J, Wang X. Electro-acupuncture stimulation improves spontaneous locomotor hyperactivity in MPTP intoxicated mice. PLoS One 2013;8:e64403.
23. Wang H, Pan Y, Xue B, Wang X, Zhao F, Jia J, Liang X, Wang X. The antioxidative effect of electro-acupuncture in a mouse model of Parkinson's disease. PLoS One 2011;6:e19790.
24. Chandran JS, Lin X, Zapata A, Hoke A, Shimoji M, Moore SO, et al. Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function. Neurobiol Dis 2008;29:505-514.
25. Liang XB, Liu XY, Li FQ, Luo Y, Lu J, Zhang WM, et al. Long-term high-frequency electro-acupuncture stimulation prevents neuronal degeneration and up-regulates BDNF mRNA in the substantia nigra and ventral tegmental area following medial forebrain bundle axotomy. Brain Res Mol Brain Res 2002;108:51-59.
26. Calkins MJ, Vargas MR, Johnson DA, Johnson JA. Astrocyte-specific overexpression of Nrf2 protects striatal neurons from mitochondrial complex II inhibition. Toxicol Sci 2010; 115: 557-568.
27. Beraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, et al. Microglial activation and antioxidant responses induced by the Parkinson's disease protein alpha-synuclein. J Neuroimmune Pharmacol 2013;8:94-117.
28. Tillerson JL, Caudle WM, Reveron ME, Miller GW. Detection of behavioral impairments correlated to neurochemical defi-cits in mice treated with moderate doses of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Exp Neurol 2002;178:80-90.
29. Sconce MD, Churchill MJ, Greene RE, Meshul CK. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease. Neuroscience 2015;299:156-274.
30. Fredriksson A, Plaznik A, Sundstrom E, Archer T. Effects of D1 and D2 agonists on spontaneous motor activity in MPTP treated mice. Pharmacol Toxicol 1994;75:36-41.
31. Schwarting RK, Sedelis M, Hofele K, Auburger GW, Huston JP. Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease. Neurotox Res 1999;1:41-56.
32. Hofele K, Sedelis M, Auburger GW, Morgan S, Huston JP, Schwarting RK. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Exp Neurol 2001;168:116-122.
33. Sedelis M, Schwarting RK, Huston JP. Behavioral phenotyp-ing of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001;125:109-125.
34. Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res 2007;85:919-934.
35. Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth PJ, et al. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2006;2:249-253.
36. Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes. Mol Neurobiol 2014;49:28-38.
37. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 2008;1147: 93-104.
38. Chun HS, Gibson GE, DeGiorgio LA, Zhang H, Kidd VJ, Son JH. Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem 2001;76:1010-1021.
39. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglial are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291.
40. O'Callaghan JP, Miller DB, Reinhard JJ. Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1, 2, 3, 6-tet-rahydropyridine. Brain Res 1990;521:73-80.
41. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009;8:382-397.
42. Zafar KS, Inayat-Hussain SH, Ross D. A comparative study of proteasomal inhibition and apoptosis induced in N27 mesencephalic cells by dopamine and MG132. J Neurochem 2007;102:913-921.
43. van Muiswinkel FL, de Vos RA, Bol JG, Andringa G, Jansen SE, Ross D, et al. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 2004;25:1253-1262.
44. Han JM, Lee YJ, Lee SY, Kim EM, Moon Y, Kim HW, Hwang O. Protective effect of sulforaphane against dopaminergic cell death. J Pharmacol Exp Ther 2007;321:249-256.
45. Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol 2013;22:11-17.
46. Schipper HM, Liberman A, Stopa EG. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp Neurol 1998;150:60-68.
47. Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D. Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J Neurochem 2009;110:469-485.